Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2012 | 09-2012 | 06-2012 | 03-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,117 | -3,782 | -1,826 | -12,210 | -9,168 |
| Depreciation Amortization | 373 | 83 | 37 | 1,022 | 1,014 |
| Accounts receivable | 106 | 106 | 106 | -64 | 34 |
| Other Working Capital | 1,128 | 1,262 | 961 | 615 | 1,715 |
| Other Operating Activity | 5,016 | 800 | 426 | 7,071 | 3,557 |
| Operating Cash Flow | $-2,493 | $-1,531 | $-296 | $-3,566 | $-2,847 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -131 | N/A | N/A | -32 | -13 |
| Investing Cash Flow | $-131 | $N/A | $N/A | $-32 | $-13 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,222 | 1,250 | N/A | 467 | N/A |
| Debt Repayment | -397 | -219 | -10 | -772 | -678 |
| Common Stock Issued | 743 | 432 | 257 | 3,846 | 3,566 |
| Financing Cash Flow | $2,568 | $1,463 | $247 | $3,540 | $2,888 |
| Beginning Cash Position | 81 | 81 | 81 | 139 | 139 |
| End Cash Position | 24 | 13 | 32 | 81 | 166 |
| Net Cash Flow | $-57 | $-68 | $-49 | $-58 | $27 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,493 | -1,531 | -296 | -3,566 | -2,847 |
| Capital Expenditure | -131 | N/A | N/A | -32 | -13 |
| Free Cash Flow | -2,624 | -1,531 | -296 | -3,598 | -2,861 |